

# Chun Jen Liu

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/5364014/chun-jen-liu-publications-by-citations.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

324  
papers

13,518  
citations

55  
h-index

105  
g-index

341  
ext. papers

15,693  
ext. citations

6.7  
avg, IF

6.1  
L-index

#	Paper	IF	Citations
324	Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. <i>Hepatology International</i> , <b>2016</b> , 10, 1-98	8.8	1288
323	Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update. <i>Hepatology International</i> , <b>2012</b> , 6, 531-61	8.8	768
322	Hepatitis B virus genotype and DNA level and hepatocellular carcinoma: a prospective study in men. <i>Journal of the National Cancer Institute</i> , <b>2005</b> , 97, 265-72	9.7	459
321	Decreased incidence of hepatocellular carcinoma in hepatitis B vaccinees: a 20-year follow-up study. <i>Journal of the National Cancer Institute</i> , <b>2009</b> , 101, 1348-55	9.7	446
320	Metabolic factors and risk of hepatocellular carcinoma by chronic hepatitis B/C infection: a follow-up study in Taiwan. <i>Gastroenterology</i> , <b>2008</b> , 135, 111-21	13.3	408
319	High levels of hepatitis B surface antigen increase risk of hepatocellular carcinoma in patients with low HBV load. <i>Gastroenterology</i> , <b>2012</b> , 142, 1140-1149.e3; quiz e13-4	13.3	362
318	The CRISPR/Cas9 System Facilitates Clearance of the Intrahepatic HBV Templates In Vivo. <i>Molecular Therapy - Nucleic Acids</i> , <b>2014</b> , 3, e186	10.7	274
317	High prevalence and mapping of pre-S deletion in hepatitis B virus carriers with progressive liver diseases. <i>Gastroenterology</i> , <b>2006</b> , 130, 1153-68	13.3	236
316	Asia-Pacific Working Party on Non-alcoholic Fatty Liver Disease guidelines 2017-Part 1: Definition, risk factors and assessment. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2018</b> , 33, 70-85	4	211
315	Quantification and genotyping of hepatitis B virus in a single reaction by real-time PCR and melting curve analysis. <i>Journal of Hepatology</i> , <b>2004</b> , 41, 659-66	13.4	188
314	Serum hepatitis B surface antigen levels help predict disease progression in patients with low hepatitis B virus loads. <i>Hepatology</i> , <b>2013</b> , 57, 441-50	11.2	183
313	Peginterferon alfa-2a plus ribavirin for the treatment of dual chronic infection with hepatitis B and C viruses. <i>Gastroenterology</i> , <b>2009</b> , 136, 496-504.e3	13.3	183
312	Familial risk of hepatocellular carcinoma among chronic hepatitis B carriers and their relatives. <i>Journal of the National Cancer Institute</i> , <b>2000</b> , 92, 1159-64	9.7	167
311	Pegylated interferon-alpha-2a plus ribavirin for treatment-naive Asian patients with hepatitis C virus genotype 1 infection: a multicenter, randomized controlled trial. <i>Clinical Infectious Diseases</i> , <b>2008</b> , 47, 1260-9	11.6	165
310	Serum hepatitis B surface antigen levels predict surface antigen loss in hepatitis B e antigen seroconverters. <i>Gastroenterology</i> , <b>2011</b> , 141, 517-25, 525.e1-2	13.3	154
309	Role of hepatitis B viral load and basal core promoter mutation in hepatocellular carcinoma in hepatitis B carriers. <i>Journal of Infectious Diseases</i> , <b>2006</b> , 193, 1258-65	7	149
308	Prevalence and risk factors for non-alcoholic fatty liver disease in Asian people who are not obese. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2012</b> , 27, 1555-60	4	141

307	Hepatitis C virus seromarkers and subsequent risk of hepatocellular carcinoma: long-term predictors from a community-based cohort study. <i>Journal of Clinical Oncology</i> , <b>2010</b> , 28, 4587-93	2.2	127
306	Long-term Effects of Hepatitis B Immunization of Infants in Preventing Liver Cancer. <i>Gastroenterology</i> , <b>2016</b> , 151, 472-480.e1	13.3	125
305	Heparanase inhibitor PI-88 as adjuvant therapy for hepatocellular carcinoma after curative resection: a randomized phase II trial for safety and optimal dosage. <i>Journal of Hepatology</i> , <b>2009</b> , 50, 958-68	13.4	125
304	Global perspective on the natural history of chronic hepatitis B: role of hepatitis B virus genotypes A to J. <i>Seminars in Liver Disease</i> , <b>2013</b> , 33, 97-102	7.3	122
303	Role of hepatitis B virus precore/core promoter mutations and serum viral load on noncirrhotic hepatocellular carcinoma: a case-control study. <i>Journal of Infectious Diseases</i> , <b>2006</b> , 194, 594-9	7	118
302	Hepatitis C virus infection and increased risk of cerebrovascular disease. <i>Stroke</i> , <b>2010</b> , 41, 2894-900	6.7	113
301	Androgen-receptor gene CAG repeats, plasma testosterone levels, and risk of hepatitis B-related hepatocellular carcinoma. <i>Journal of the National Cancer Institute</i> , <b>2000</b> , 92, 2023-8	9.7	105
300	Determinants of spontaneous surface antigen loss in hepatitis B e antigen-negative patients with a low viral load. <i>Hepatology</i> , <b>2012</b> , 55, 68-76	11.2	104
299	Body-mass index and progression of hepatitis B: a population-based cohort study in men. <i>Journal of Clinical Oncology</i> , <b>2008</b> , 26, 5576-82	2.2	94
298	Ribavirin and interferon is effective for hepatitis C virus clearance in hepatitis B and C dually infected patients. <i>Hepatology</i> , <b>2003</b> , 37, 568-76	11.2	94
297	Hepatitis B viral genotypes and lamivudine resistance. <i>Journal of Hepatology</i> , <b>2002</b> , 36, 303-4	13.4	94
296	Hepatitis B viral factors in HBeAg-negative carriers with persistently normal serum alanine aminotransferase levels. <i>Hepatology</i> , <b>2007</b> , 45, 1193-8	11.2	93
295	Transmission of occult hepatitis B virus by transfusion to adult and pediatric recipients in Taiwan. <i>Journal of Hepatology</i> , <b>2006</b> , 44, 39-46	13.4	93
294	Temporal relationship between hepatitis B virus enhancer II/basal core promoter sequence variation and risk of hepatocellular carcinoma. <i>Gut</i> , <b>2008</b> , 57, 91-7	19.2	86
293	RNA interference-mediated control of hepatitis B virus and emergence of resistant mutant. <i>Gastroenterology</i> , <b>2005</b> , 128, 708-16	13.3	86
292	Therapeutic implications of hepatitis B virus genotypes. <i>Liver International</i> , <b>2005</b> , 25, 1097-107	7.9	86
291	Association of cytokine and DNA repair gene polymorphisms with hepatitis B-related hepatocellular carcinoma. <i>International Journal of Epidemiology</i> , <b>2005</b> , 34, 1310-8	7.8	86
290	Epidemiology of HBV infection in Asian blood donors: emphasis on occult HBV infection and the role of NAT. <i>Journal of Clinical Virology</i> , <b>2006</b> , 36 Suppl 1, S33-44	14.5	85

289	Polymorphisms in XRCC1 and glutathione S-transferase genes and hepatitis B-related hepatocellular carcinoma. <i>Journal of the National Cancer Institute</i> , <b>2003</b> , 95, 1485-8	9.7	84
288	Viral hepatocarcinogenesis: from infection to cancer. <i>Liver International</i> , <b>2008</b> , 28, 175-88	7.9	83
287	Higher proportion of viral basal core promoter mutant increases the risk of liver cirrhosis in hepatitis B carriers. <i>Gut</i> , <b>2015</b> , 64, 292-302	19.2	82
286	Influence of Metabolic Risk Factors on Risk of Hepatocellular Carcinoma and Liver-Related Death in Men With Chronic Hepatitis B: A Large Cohort Study. <i>Gastroenterology</i> , <b>2017</b> , 153, 1006-1017.e5	13.3	81
285	Efficacy of Ledipasvir and Sofosbuvir Treatment of HCV Infection in Patients Coinfected With HBV. <i>Gastroenterology</i> , <b>2018</b> , 154, 989-997	13.3	79
284	Pegylated interferon- $\alpha$ with or without low-dose ribavirin for treatment-naïve patients with hepatitis C virus genotype 1 receiving hemodialysis: a randomized trial. <i>Annals of Internal Medicine</i> , <b>2013</b> , 159, 729-38	8	79
283	High hepatitis C viral load is associated with insulin resistance in patients with chronic hepatitis C. <i>Liver International</i> , <b>2008</b> , 28, 271-7	7.9	77
282	Quantitative hepatitis B core antibody levels in the natural history of hepatitis B virus infection. <i>Clinical Microbiology and Infection</i> , <b>2015</b> , 21, 197-203	9.5	73
281	Serum hepatitis B surface antigen concentration correlates with HBV DNA level in patients with chronic hepatitis B. <i>Antiviral Therapy</i> , <b>2010</b> , 15, 1133-9	1.6	72
280	Association of chronic hepatitis B virus infection with insulin resistance and hepatic steatosis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2008</b> , 23, 779-82	4	72
279	The Asia-Pacific Working Party on Non-alcoholic Fatty Liver Disease guidelines 2017-Part 2: Management and special groups. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2018</b> , 33, 86-98 <sup>4</sup>		71
278	Effect of host and viral factors on hepatitis B e antigen-positive chronic hepatitis B patients receiving pegylated interferon- $\alpha$ therapy. <i>Antiviral Therapy</i> , <b>2011</b> , 16, 629-37	1.6	71
277	Long-term tracking of hepatitis B viral load and the relationship with risk for hepatocellular carcinoma in men. <i>Carcinogenesis</i> , <b>2008</b> , 29, 106-12	4.6	66
276	Transient elastography to assess hepatic fibrosis in hemodialysis chronic hepatitis C patients. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , <b>2011</b> , 6, 1057-65	6.9	64
275	Comparison of a 6-month course peginterferon alpha-2b plus ribavirin and interferon alpha-2b plus ribavirin in treating Chinese patients with chronic hepatitis C in Taiwan. <i>Journal of Viral Hepatitis</i> , <b>2005</b> , 12, 283-91	3.4	63
274	Role of reproductive factors in hepatocellular carcinoma: Impact on hepatitis B- and C-related risk. <i>Hepatology</i> , <b>2003</b> , 38, 1393-400	11.2	61
273	A prospective study characterizing full-length hepatitis B virus genomes during acute exacerbation. <i>Gastroenterology</i> , <b>2003</b> , 124, 80-90	13.3	60
272	Serum adiponectin correlates with viral characteristics but not histologic features in patients with chronic hepatitis C. <i>Journal of Hepatology</i> , <b>2005</b> , 43, 235-42	13.4	59

271	Quantitative hepatitis B core antibody level may help predict treatment response in chronic hepatitis B patients. <i>Gut</i> , <b>2013</b> , 62, 182-4	19.2	58
270	Sustained hepatitis C virus clearance and increased hepatitis B surface antigen seroclearance in patients with dual chronic hepatitis C and B during posttreatment follow-up. <i>Hepatology</i> , <b>2013</b> , 57, 2135-42	11.2	55
269	Serum microRNA-122 level correlates with virologic responses to pegylated interferon therapy in chronic hepatitis C. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2013</b> , 110, 7844-9	11.5	55
268	Hepatitis B virus-related hepatocellular carcinoma: epidemiology and pathogenic role of viral factors. <i>Journal of the Chinese Medical Association</i> , <b>2007</b> , 70, 141-5	2.8	55
267	Association of IL28B gene variations with mathematical modeling of viral kinetics in chronic hepatitis C patients with IFN plus ribavirin therapy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2011</b> , 108, 3719-24	11.5	54
266	Comparison of Abbott RealTime HCV Genotype II with Versant line probe assay 2.0 for hepatitis C virus genotyping. <i>Journal of Clinical Microbiology</i> , <b>2015</b> , 53, 1754-7	9.7	51
265	Pegylated interferon alpha-2a versus standard interferon alpha-2a for treatment-naive dialysis patients with chronic hepatitis C: a randomised study. <i>Gut</i> , <b>2008</b> , 57, 525-30	19.2	51
264	Sorafenib and its derivative SC-1 exhibit antifibrotic effects through signal transducer and activator of transcription 3 inhibition. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2015</b> , 112, 7243-8	11.5	49
263	Molecular mechanism and treatment of viral hepatitis-related liver fibrosis. <i>International Journal of Molecular Sciences</i> , <b>2014</b> , 15, 10578-604	6.3	48
262	Impact of hepatitis B virus infection on metabolic profiles and modifying factors. <i>Journal of Viral Hepatitis</i> , <b>2012</b> , 19, e48-57	3.4	48
261	Community and personal risk factors for hepatitis C virus infection: a survey of 23,820 residents in Taiwan in 1991-2. <i>Gut</i> , <b>2011</b> , 60, 688-94	19.2	47
260	Hepatitis B virus variants in patients receiving lamivudine treatment with breakthrough hepatitis evaluated by serial viral loads and full-length viral sequences. <i>Hepatology</i> , <b>2001</b> , 34, 583-9	11.2	47
259	Hepatitis B genotypes correlate with tumor recurrence after curative resection of hepatocellular carcinoma. <i>Clinical Gastroenterology and Hepatology</i> , <b>2004</b> , 2, 64-71	6.9	46
258	Adjuvant heparanase inhibitor PI-88 therapy for hepatocellular carcinoma recurrence. <i>World Journal of Gastroenterology</i> , <b>2014</b> , 20, 11384-93	5.6	46
257	High Level of Hepatitis B Core-Related Antigen Associated With Increased Risk of Hepatocellular Carcinoma in Patients With Chronic HBV Infection of Intermediate Viral Load. <i>Gastroenterology</i> , <b>2019</b> , 157, 1518-1529.e3	13.3	45
256	Circulating programmed death-1 as a marker for sustained high hepatitis B viral load and risk of hepatocellular carcinoma. <i>PLoS ONE</i> , <b>2014</b> , 9, e95870	3.7	45
255	Influences of tobacco and alcohol use on hepatocellular carcinoma survival. <i>International Journal of Cancer</i> , <b>2012</b> , 131, 2612-21	7.5	45
254	Distinct evolution and predictive value of hepatitis B virus precore and basal core promoter mutations in interferon-induced hepatitis B e antigen seroconversion. <i>Hepatology</i> , <b>2013</b> , 57, 934-43	11.2	45

253	Insulin, glucose and hepatocellular carcinoma risk in male hepatitis B carriers: results from 17-year follow-up of a population-based cohort. <i>Carcinogenesis</i> , <b>2011</b> , 32, 876-81	4.6	44
252	Dual chronic hepatitis B virus and hepatitis C virus infection. <i>Hepatology International</i> , <b>2009</b> , 3, 517-25	8.8	43
251	HBsAg profiles in patients receiving peginterferon alfa-2a plus ribavirin for the treatment of dual chronic infection with hepatitis B and C viruses. <i>Journal of Infectious Diseases</i> , <b>2010</b> , 202, 86-92	7	42
250	Higher lifetime chance of spontaneous surface antigen loss in hepatitis B carriers with genotype C infection. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2015</b> , 41, 949-60	6.1	41
249	Distinct Relapse Rates and Risk Predictors After Discontinuing Tenofovir and Entecavir Therapy. <i>Journal of Infectious Diseases</i> , <b>2018</b> , 217, 1193-1201	7	41
248	Young chronic hepatitis B patients with nucleos(t)ide analogue-induced hepatitis B e antigen seroconversion have a higher risk of HBV reactivation. <i>Journal of Infectious Diseases</i> , <b>2012</b> , 206, 1521-31	7	41
247	Serum hepatitis B virus-DNA levels correlate with long-term adverse outcomes in spontaneous hepatitis B e antigen seroconverters. <i>Journal of Infectious Diseases</i> , <b>2012</b> , 205, 54-63	7	41
246	Genotypic dominance and novel recombinations in HBV genotype B and C co-infected intravenous drug users. <i>Journal of Medical Virology</i> , <b>2004</b> , 73, 13-22	19.7	41
245	Low incidence of hepatitis C virus transmission between spouses: a prospective study. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2000</b> , 15, 391-5	4	41
244	Hepatitis B virus reactivation in patients receiving cancer chemotherapy: natural history, pathogenesis, and management. <i>Hepatology International</i> , <b>2013</b> , 7, 316-26	8.8	40
243	Host genetic factors affecting spontaneous HBsAg seroclearance in chronic hepatitis B patients. <i>PLoS ONE</i> , <b>2013</b> , 8, e53008	3.7	39
242	Precore/core promoter mutations and genotypes of hepatitis B virus in chronic hepatitis B patients with fulminant or subfulminant hepatitis. <i>Journal of Medical Virology</i> , <b>2004</b> , 72, 545-50	19.7	39
241	Long-term risk of tuberculosis in haematopoietic stem cell transplant recipients: a 10-year nationwide study. <i>International Journal of Tuberculosis and Lung Disease</i> , <b>2015</b> , 19, 58-64	2.1	38
240	Treatment of patients with dual hepatitis C and B by peginterferon and ribavirin reduced risk of hepatocellular carcinoma and mortality. <i>Gut</i> , <b>2014</b> , 63, 506-14	19.2	38
239	Interleukin 28B genetic polymorphisms and viral factors help identify HCV genotype-1 patients who benefit from 24-week pegylated interferon plus ribavirin therapy. <i>Antiviral Therapy</i> , <b>2012</b> , 17, 477-84	1.6	38
238	Differential effects of interferon and lamivudine on serum HBV RNA inhibition in patients with chronic hepatitis B. <i>Antiviral Therapy</i> , <b>2010</b> , 15, 177-84	1.6	38
237	Interferon alpha-2b with and without ribavirin in the treatment of hepatitis B e antigen-positive chronic hepatitis B: a randomized study. <i>Hepatology</i> , <b>2006</b> , 43, 742-9	11.2	38
236	Viral factors correlate with hepatitis B e antigen seroconversion in patients with chronic hepatitis B. <i>Liver International</i> , <b>2006</b> , 26, 949-55	7.9	38

235	Risk stratification of hepatocellular carcinoma in hepatitis B virus e antigen-negative carriers by combining viral biomarkers. <i>Journal of Infectious Diseases</i> , <b>2013</b> , 208, 584-93	7	37
234	Lamivudine treatment for hepatitis B reactivation in HBsAg carriers after organ transplantation: a 4-year experience. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2001</b> , 16, 1001-8	4	37
233	Advancing the global public health agenda for NAFLD: a consensus statement. <i>Nature Reviews Gastroenterology and Hepatology</i> , <b>2021</b> ,	24.2	37
232	Permanent Inactivation of HBV Genomes by CRISPR/Cas9-Mediated Non-cleavage Base Editing. <i>Molecular Therapy - Nucleic Acids</i> , <b>2020</b> , 20, 480-490	10.7	36
231	Hepatitis B Virus Reactivation in Patients Receiving Interferon-Free Direct-Acting Antiviral Agents for Chronic Hepatitis C Virus Infection. <i>Open Forum Infectious Diseases</i> , <b>2017</b> , 4, ofx028	1	35
230	High prevalence of mixed genotype infections in hepatitis B virus infected intravenous drug users. <i>Journal of Medical Virology</i> , <b>2004</b> , 74, 536-42	19.7	35
229	Asian consensus on the relationship between obesity and gastrointestinal and liver diseases. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2016</b> , 31, 1405-13	4	35
228	Natural course and treatment of dual hepatitis B virus and hepatitis C virus infections. <i>Journal of the Formosan Medical Association</i> , <b>2005</b> , 104, 783-91	3.2	35
227	2020 Taiwan consensus statement on the management of hepatitis C: Part (II) special populations. <i>Journal of the Formosan Medical Association</i> , <b>2020</b> , 119, 1135-1157	3.2	34
226	Naturally occurring hepatitis B surface gene variants in chronic hepatitis B virus infection: correlation with viral serotypes and clinical stages of liver disease. <i>Journal of Medical Virology</i> , <b>2002</b> , 68, 50-9	19.7	34
225	Hepatitis B genotypes and precore/basal core promoter mutants in HBeAg-negative chronic hepatitis B. <i>Journal of Gastroenterology</i> , <b>2002</b> , 37, 283-7	6.9	34
224	Significance of definitions of relapse after discontinuation of oral antivirals in HBeAg-negative chronic hepatitis B. <i>Hepatology</i> , <b>2018</b> , 68, 415-424	11.2	32
223	Peginterferon alfa-2a with or without low-dose ribavirin for treatment-naive patients with hepatitis C virus genotype 2 receiving haemodialysis: a randomised trial. <i>Gut</i> , <b>2015</b> , 64, 303-11	19.2	32
222	Association of lipid profiles with hepatitis C viral load in chronic hepatitis C patients with genotype 1 or 2 infection. <i>American Journal of Gastroenterology</i> , <b>2009</b> , 104, 598-604	0.7	32
221	Hepatitis B virus core variants modify natural course of viral infection and hepatocellular carcinoma progression. <i>Gastroenterology</i> , <b>2009</b> , 137, 1687-97	13.3	32
220	Natural course and treatment of hepatitis D virus infection. <i>Journal of the Formosan Medical Association</i> , <b>2006</b> , 105, 869-81	3.2	32
219	Fibrosis-4 Index Helps Identify HBV Carriers With the Lowest Risk of Hepatocellular Carcinoma. <i>American Journal of Gastroenterology</i> , <b>2017</b> , 112, 1564-1574	0.7	31
218	Development of risk scoring system for stratifying population for hepatocellular carcinoma screening. <i>Hepatology</i> , <b>2015</b> , 61, 1934-44	11.2	31

217	Hepatitis C viral infection increases the risk of lymphoid-neoplasms: A population-based cohort study. <i>Hepatology</i> , <b>2016</b> , 63, 721-30	11.2	31
216	Serum Biomarkers Predictive of Significant Fibrosis and Cirrhosis in Chronic Hepatitis B. <i>Journal of Clinical Gastroenterology</i> , <b>2015</b> , 49, 705-13	3	30
215	High serum adiponectin correlates with advanced liver disease in patients with chronic hepatitis B virus infection. <i>Hepatology International</i> , <b>2009</b> , 3, 364-70	8.8	30
214	Genetic polymorphisms in interferon pathway and response to interferon treatment in hepatitis B patients: A pilot study. <i>Hepatology</i> , <b>2002</b> , 36, 1416-24	11.2	30
213	Fine mapping of hepatitis B virus pre-S deletion and its association with hepatocellular carcinoma. <i>Liver International</i> , <b>2012</b> , 32, 1373-81	7.9	29
212	The clinical significance of occult hepatitis B transfusion in Taiwan--a look-back study. <i>Transfusion Medicine</i> , <b>2011</b> , 21, 33-41	1.3	29
211	Vitamin D receptor gene polymorphisms and distinct clinical phenotypes of hepatitis B carriers in Taiwan. <i>Genes and Immunity</i> , <b>2010</b> , 11, 87-93	4.4	29
210	Increased risk for hepatitis B-related liver cirrhosis in relatives of patients with hepatocellular carcinoma in northern Taiwan. <i>International Journal of Epidemiology</i> , <b>2002</b> , 31, 1008-15	7.8	28
209	2020 Taiwan consensus statement on the management of hepatitis C: part (I) general population. <i>Journal of the Formosan Medical Association</i> , <b>2020</b> , 119, 1019-1040	3.2	27
208	Association of metabolic profiles with hepatic fibrosis in chronic hepatitis C patients with genotype 1 or 2 infection. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2010</b> , 25, 970-7	4	27
207	The ratio of aminotransferase to platelets is a useful index for predicting hepatic fibrosis in hemodialysis patients with chronic hepatitis C. <i>Kidney International</i> , <b>2010</b> , 78, 103-9	9.9	27
206	Metabolic profiles in patients with chronic hepatitis C: a case-control study. <i>Hepatology International</i> , <b>2008</b> , 2, 250-7	8.8	27
205	Evolution of Hepatitis B virus in an acute hepatitis B patient co-infected with genotypes B and C. <i>Journal of General Virology</i> , <b>2006</b> , 87, 39-49	4.9	27
204	Increased risk of hepatocellular carcinoma in chronic hepatitis C patients with new onset diabetes: a nation-wide cohort study. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2015</b> , 42, 902-11	6.1	26
203	Pegylated interferon alfa-2a monotherapy for hemodialysis patients with acute hepatitis C. <i>Clinical Infectious Diseases</i> , <b>2010</b> , 51, 541-9	11.6	26
202	Genetic polymorphisms in interferon pathway and response to interferon treatment in hepatitis B patients: A pilot study. <i>Hepatology</i> , <b>2002</b> , 36, 1416-1424	11.2	26
201	Amebic liver abscess and human immunodeficiency virus infection: a report of three cases. <i>Journal of Clinical Gastroenterology</i> , <b>2001</b> , 33, 64-8	3	26
200	Hepatitis B virus basal core promoter mutation and DNA load correlate with expression of hepatitis B core antigen in patients with chronic hepatitis B. <i>Journal of Infectious Diseases</i> , <b>2009</b> , 199, 742-9	7	25



199	Esophageal varices: noninvasive diagnosis with duplex Doppler US in patients with compensated cirrhosis. <i>Radiology</i> , <b>2008</b> , 248, 132-9	20.5	25
198	Taiwan consensus statement on the management of chronic hepatitis B. <i>Journal of the Formosan Medical Association</i> , <b>2019</b> , 118, 7-38	3.2	25
197	Factors affecting early viral load decline of Asian chronic hepatitis C patients receiving pegylated interferon plus ribavirin therapy. <i>Antiviral Therapy</i> , <b>2009</b> , 14, 45-54	1.6	25
196	Hepatitis B virus genotype B has an earlier emergence of lamivudine resistance than genotype C. <i>Antiviral Therapy</i> , <b>2009</b> , 14, 1157-63	1.6	24
195	Noninvasive diagnosis of hepatic fibrosis in patients with chronic hepatitis C by splenic Doppler impedance index. <i>Clinical Gastroenterology and Hepatology</i> , <b>2007</b> , 5, 1199-1206.e1	6.9	24
194	Androgen receptor exon 1 CAG repeat length and risk of hepatocellular carcinoma in women. <i>Hepatology</i> , <b>2002</b> , 36, 156-63	11.2	24
193	Nonalcoholic fatty liver disease: updates in noninvasive diagnosis and correlation with cardiovascular disease. <i>World Journal of Gastroenterology</i> , <b>2014</b> , 20, 7718-29	5.6	24
192	High prevalence of occult hepatitis B virus infection in Taiwanese intravenous drug users. <i>Journal of Medical Virology</i> , <b>2007</b> , 79, 1674-8	19.7	23
191	Evolution of eGFR in chronic HCV patients receiving sofosbuvir-based or sofosbuvir-free direct-acting antivirals. <i>Journal of Hepatology</i> , <b>2020</b> , 72, 839-846	13.4	23
190	Genetic Variability of Hepatitis B virus and Response to Antiviral Therapy. <i>Antiviral Therapy</i> , <b>2008</b> , 13, 613-624	1.6	23
189	Sofosbuvir-based Interferon-Free Direct Acting Antiviral Regimens for Heart Transplant Recipients With Chronic Hepatitis C Virus Infection. <i>Clinical Infectious Diseases</i> , <b>2018</b> , 66, 289-292	11.6	22
188	Pegylated interferon alpha-2a plus low-dose ribavirin for the retreatment of dialysis chronic hepatitis C patients who relapsed from prior interferon monotherapy. <i>Gut</i> , <b>2009</b> , 58, 314-6	19.2	22
187	Evolution of precore/core promoter mutations in hepatitis B carriers with hepatitis B e antigen seroreversion. <i>Journal of Medical Virology</i> , <b>2004</b> , 74, 237-45	19.7	22
186	Serum cytokine/chemokine profiles in acute exacerbation of chronic hepatitis B: clinical and mechanistic implications. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2014</b> , 29, 1629-36	4	21
185	Effects of hepatitis B virus precore and basal core promoter mutations on the expression of viral antigens: genotype B vs C. <i>Journal of Viral Hepatitis</i> , <b>2011</b> , 18, e482-90	3.4	21
184	Interleukin 28B genetic polymorphisms play a minor role in identifying optimal treatment duration in HCV genotype 1 slow responders to pegylated interferon plus ribavirin. <i>Antiviral Therapy</i> , <b>2012</b> , 17, 1059-67	1.6	21
183	Real-world effectiveness and safety of paritaprevir/ritonavir, ombitasvir, and dasabuvir with or without ribavirin for patients with chronic hepatitis C virus genotype 1b infection in Taiwan. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2018</b> , 33, 710-717	4	21
182	Plasma adipokines and risk of hepatocellular carcinoma in chronic hepatitis B virus-infected carriers: a prospective study in taiwan. <i>Cancer Epidemiology Biomarkers and Prevention</i> , <b>2014</b> , 23, 1659-7†		20

181	Diminished hepatic IFN response following HCV clearance triggers HBV reactivation in coinfection. <i>Journal of Clinical Investigation</i> , <b>2020</b> , 130, 3205-3220	15.9	20
180	Updates on the treatment and outcomes of dual chronic hepatitis C and B virus infection. <i>World Journal of Gastroenterology</i> , <b>2014</b> , 20, 2955-61	5.6	20
179	Generic sofosbuvir-based interferon-free direct acting antiviral agents for patients with chronic hepatitis C virus infection: a real-world multicenter observational study. <i>Scientific Reports</i> , <b>2018</b> , 8, 13694-9	4.9	20
178	Influence of Metabolic Syndrome, Viral Genotype and Antiviral Therapy on Superimposed Fatty Liver Disease in Chronic Hepatitis C. <i>Antiviral Therapy</i> , <b>2005</b> , 10, 405-415	1.6	20
177	Chronic hepatitis B is associated with an increased risk of B-cell non-Hodgkin lymphoma and multiple myeloma. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2019</b> , 49, 589-598	6.1	19
176	Generic velpatasvir plus sofosbuvir for hepatitis C virus infection in patients with or without human immunodeficiency virus coinfection. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2018</b> , 47, 1690-1698	6.1	19
175	Hepatitis B viraemia: its heritability and association with common genetic variation in the interferon gamma signalling pathway. <i>Gut</i> , <b>2011</b> , 60, 99-107	19.2	19
174	Clinicopathological differences between hepatitis B viral genotype B- and C-related resectable hepatocellular carcinoma. <i>Journal of Viral Hepatitis</i> , <b>2007</b> , 14, 64-9	3.4	19
173	Prevalence and clinical implications of HFE gene mutations (C282Y and H63D) in patients with chronic hepatitis B and C in Taiwan. <i>Liver International</i> , <b>2005</b> , 25, 214-9	7.9	19
172	Liver Gene Expression Profiles Correlate with Virus Infection and Response to Interferon Therapy in Chronic Hepatitis B Patients. <i>Scientific Reports</i> , <b>2016</b> , 6, 31349	4.9	18
171	Incorporating Serum Level of Hepatitis B Surface Antigen or Omitting Level of Hepatitis B Virus DNA Does not Affect Calculation of Risk for Hepatocellular Carcinoma in Patients Without Cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , <b>2016</b> , 14, 461-468.e2	6.9	18
170	Risk of extrathymic cancer in patients with myasthenia gravis in Taiwan: a nationwide population-based study. <i>European Journal of Neurology</i> , <b>2012</b> , 19, 746-51	6	18
169	Milder clinical manifestation of scrub typhus in Kinmen, Taiwan. <i>Journal of the Formosan Medical Association</i> , <b>2013</b> , 112, 201-7	3.2	18
168	Incidence and risk analysis of aortic aneurysm and aortic dissection among patients with systemic lupus erythematosus: a nationwide population-based study in Taiwan. <i>Lupus</i> , <b>2014</b> , 23, 665-71	2.6	18
167	The non-structural 5A protein of hepatitis C virus exhibits genotypic differences in interferon antagonism. <i>Journal of Hepatology</i> , <b>2008</b> , 49, 899-907	13.4	18
166	Origin of serum hepatitis B virus in acute exacerbation: comparison with HBV in the liver and from other exacerbation. <i>Hepatology</i> , <b>2004</b> , 40, 310-17	11.2	18
165	Synergistic Effect of Hyperglycemia and Helicobacterpylori Infection Status on Colorectal Adenoma Risk. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2017</b> , 102, 2744-2750	5.6	17
164	Long-term effect of interferon plus ribavirin on hepatitis B surface antigen seroclearance in patients dually infected with hepatitis B and C viruses. <i>PLoS ONE</i> , <b>2011</b> , 6, e20752	3.7	17

163	Treatment of patients with dual hepatitis C virus and hepatitis B virus infection: resolved and unresolved issues. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2014</b> , 29, 26-30	4	16
162	Consolidation therapy for HBeAg-positive Asian chronic hepatitis B patients receiving lamivudine treatment: a multicentre study. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2013</b> , 68, 2332-8	5.1	16
161	Longitudinal change of HBsAg in HBeAg-negative patients with genotype B or C infection. <i>PLoS ONE</i> , <b>2013</b> , 8, e55916	3.7	16
160	A higher alanine aminotransferase level correlates with earlier hepatitis B e antigen seroconversion in lamivudine-treated chronic hepatitis B patients. <i>Liver International</i> , <b>2008</b> , 28, 1034-41	7.9	16
159	Lower serum viral loads in young patients with hepatitis-B-virus-related hepatocellular carcinoma. <i>Journal of Viral Hepatitis</i> , <b>2007</b> , 14, 153-60	3.4	16
158	Early viral kinetics during treatment of chronic hepatitis C virus infection with pegylated interferon alpha plus ribavirin in Taiwan. <i>Intervirology</i> , <b>2007</b> , 50, 310-5	2.5	16
157	Localization of a susceptibility locus for hepatocellular carcinoma to chromosome 4q in a hepatitis B hyperendemic area. <i>Oncogene</i> , <b>2006</b> , 25, 3219-24	9.2	16
156	Combination Therapy for Chronic Hepatitis B: Current Updates and Perspectives. <i>Gut and Liver</i> , <b>2017</b> , 11, 590-603	4.8	16
155	Hepatitis B Surface Antigen Loss and Hepatocellular Carcinoma Development in Patients With Dual Hepatitis B and C Infection. <i>Medicine (United States)</i> , <b>2016</b> , 95, e2995	1.8	16
154	Genome-wide identification of blood DNA methylation patterns associated with early-onset hepatocellular carcinoma development in hepatitis B carriers. <i>Molecular Carcinogenesis</i> , <b>2017</b> , 56, 425-435	5	15
153	HEV superinfection accelerates disease progression in patients with chronic HBV infection and increases mortality in those with cirrhosis. <i>Journal of Hepatology</i> , <b>2020</b> , 72, 1105-1111	13.4	15
152	Hyperglycemia combined infection increases risk of synchronous colorectal adenoma and carotid artery plaque. <i>Oncotarget</i> , <b>2017</b> , 8, 108655-108664	3.3	15
151	Serum interleukin 6 level correlates with outcomes of acute exacerbation of chronic hepatitis B. <i>Hepatology International</i> , <b>2012</b> , 6, 591-7	8.8	15
150	Evidence for association with hepatocellular carcinoma at the PAPSS1 locus on chromosome 4q25 in a family-based study. <i>European Journal of Human Genetics</i> , <b>2009</b> , 17, 1250-9	5.3	15
149	Characterization of interleukin 8 in woodchucks with chronic hepatitis B and hepatocellular carcinoma. <i>Genes and Immunity</i> , <b>2009</b> , 10, 27-36	4.4	15
148	Clinical aspects and outcomes of volunteer blood donors testing positive for hepatitis-C virus infection in Taiwan: a prospective study. <i>Liver International</i> , <b>2003</b> , 23, 148-55	7.9	15
147	Clinical and Histologic Features of Patients with Biopsy-Proven Metabolic Dysfunction-Associated Fatty Liver Disease. <i>Gut and Liver</i> , <b>2021</b> , 15, 451-458	4.8	15
146	Fibrosis-4 index predicts cirrhosis risk and liver-related mortality in 2075 patients with chronic HBV infection. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2018</b> , 47, 1480-1489	6.1	14

145	Hepatitis B surface antigen level complements viral load in predicting viral reactivation in spontaneous HBeAg seroconverters. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2014</b> , 29, 1242-9	4	14
144	Minimal role of GB virus-C/hepatitis G virus in fulminant and subfulminant hepatitis in Taiwan. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>1999</b> , 14, 352-7	4	14
143	Smoking and Hepatitis B Virus-Related Hepatocellular Carcinoma Risk: The Mediating Roles of Viral Load and Alanine Aminotransferase. <i>Hepatology</i> , <b>2019</b> , 69, 1412-1425	11.2	14
142	Real-world effectiveness of direct-acting antiviral agents for chronic hepatitis C in Taiwan: Real-world data. <i>Journal of Microbiology, Immunology and Infection</i> , <b>2020</b> , 53, 569-577	8.5	14
141	Clinical Efficacy and Post-Treatment Seromarkers Associated with the Risk of Hepatocellular Carcinoma among Chronic Hepatitis C Patients. <i>Scientific Reports</i> , <b>2017</b> , 7, 3718	4.9	13
140	Impact of occult hepatitis B on the clinical outcomes of patients with chronic hepatitis C virus infection: A 10-year follow-up. <i>Journal of the Formosan Medical Association</i> , <b>2017</b> , 116, 697-704	3.2	13
139	Use of azathioprine for graft-vs-host disease is the major risk for development of secondary malignancies after haematopoietic stem cell transplantation: a nationwide population-based study. <i>British Journal of Cancer</i> , <b>2015</b> , 112, 177-84	8.7	13
138	Clinical significance and evolution of hepatic HBsAg expression in HBeAg-positive patients receiving interferon therapy. <i>Journal of Gastroenterology</i> , <b>2014</b> , 49, 356-62	6.9	13
137	The risky body mass index ranges for significant hepatitis B viral load: A campus-based study. <i>Obesity Research and Clinical Practice</i> , <b>2012</b> , 6, e1-e90	5.4	13
136	Increased incidence of gastroesophageal reflux disease in patients with chronic hepatitis B virus infection. <i>Hepatology International</i> , <b>2010</b> , 4, 585-93	8.8	13
135	Subgenotypes of hepatitis B virus genotype C do not correlate with disease progression of chronic hepatitis B in Taiwan. <i>Liver International</i> , <b>2007</b> , 27, 983-8	7.9	13
134	Overlap lamivudine treatment in patients with chronic hepatitis B receiving adefovir for lamivudine-resistant viral mutants. <i>Journal of Viral Hepatitis</i> , <b>2006</b> , 13, 387-95	3.4	13
133	End-of-treatment virologic response does not predict relapse after lamivudine treatment for chronic hepatitis B. <i>World Journal of Gastroenterology</i> , <b>2004</b> , 10, 3574-8	5.6	13
132	Sofosbuvir-based direct acting antiviral therapies for patients with hepatitis C virus genotype 2 infection. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2019</b> , 34, 1620-1625	4	12
131	Glecaprevir/pibrentasvir for patients with chronic hepatitis C virus infection and severe renal impairment. <i>Journal of Viral Hepatitis</i> , <b>2020</b> , 27, 568-575	3.4	12
130	Serum p53 gene polymorphisms and severity of hepatitis B or C-related chronic liver diseases in Taiwan. <i>Hepatology International</i> , <b>2011</b> , 5, 814-21	8.8	12
129	Differential clinical and virologic impact of hepatitis B virus genotypes B and C on HIV-coinfected patients receiving lamivudine-containing highly active antiretroviral therapy. <i>Clinical Infectious Diseases</i> , <b>2012</b> , 54, 548-55	11.6	12
128	Association of adjuvant antiviral therapy with risk of cancer progression and deaths in patients with hepatitis-B-virus-related hepatocellular carcinoma following curative treatment: a nationwide cohort study. <i>PLoS ONE</i> , <b>2014</b> , 9, e102051	3.7	12

127	Mother-to-infant transmission of hepatitis B virus: challenges and perspectives. <i>Hepatology International</i> , <b>2017</b> , 11, 481-484	8.8	11
126	Clinical significance of circulating miR-122 in patients with dual chronic hepatitis B and C virus infection. <i>Hepatology International</i> , <b>2015</b> , 9, 35-42	8.8	11
125	A noninvasive diagnosis of hepatic fibrosis by BioFibroScore <sup>®</sup> in chronic hepatitis C patients. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2018</b> , 33, 291-297	4	11
124	Peginterferon plus Ribavirin for HIV-infected Patients with Treatment-Naïve Acute or Chronic HCV Infection in Taiwan: A Prospective Cohort Study. <i>Scientific Reports</i> , <b>2015</b> , 5, 17410	4.9	11
123	Clinical and virological features of occult hepatitis B in patients with HBsAg seroclearance post-treatment or spontaneously. <i>Liver International</i> , <b>2014</b> , 34, e71-9	7.9	11
122	Impact of genetic heterogeneity in polymerase of hepatitis B virus on dynamics of viral load and hepatitis B progression. <i>PLoS ONE</i> , <b>2013</b> , 8, e70169	3.7	11
121	Glecaprevir/pibrentasvir for patients with chronic hepatitis C virus infection: Real-world effectiveness and safety in Taiwan. <i>Liver International</i> , <b>2020</b> , 40, 758-768	7.9	11
120	How Does Aging Affect Presentation and Management of Biliary Stones?. <i>Journal of the American Geriatrics Society</i> , <b>2016</b> , 64, 2330-2335	5.6	11
119	Perspectives on dual hepatitis B and C infection in Taiwan. <i>Journal of the Formosan Medical Association</i> , <b>2016</b> , 115, 298-305	3.2	10
118	Allergic rhinitis and risk of erectile dysfunction--a nationwide population-based study. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , <b>2013</b> , 68, 440-5	9.3	10
117	Functional impairment of dendritic cells in patients infected with hepatitis C virus genotype 1 who failed peginterferon plus ribavirin therapy. <i>Journal of Medical Virology</i> , <b>2011</b> , 83, 1212-20	19.7	10
116	Hepatitis C Virus and Hepatitis B Virus Co-Infection. <i>Viruses</i> , <b>2020</b> , 12,	6.2	10
115	Decreased Colorectal Adenoma Risk After Helicobacter pylori Eradication: A Retrospective Cohort Study. <i>Clinical Infectious Diseases</i> , <b>2019</b> , 68, 2105-2113	11.6	10
114	Factors affecting early viral load decline of Asian chronic hepatitis C patients receiving pegylated interferon plus ribavirin therapy. <i>Antiviral Therapy</i> , <b>2009</b> , 14, 45-54	1.6	10
113	Association of baseline viral factors with response to lamivudine therapy in chronic hepatitis B patients with high serum alanine aminotransferase levels. <i>Antiviral Therapy</i> , <b>2009</b> , 14, 203-210	1.6	10
112	Decreased neonatal hepatitis B virus (HBV) viremia by maternal tenofovir treatment predicts reduced chronic HBV infection in children born to highly viremic mothers. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2019</b> , 50, 306-316	6.1	9
111	Consensus cost-effectiveness model for treatment of chronic hepatitis B in Asia Pacific countries. <i>Hepatology International</i> , <b>2014</b> , 8, 382-94	8.8	9
110	IL-21R gene polymorphisms and serum IL-21 levels predict virological response to interferon-based therapy in Asian chronic hepatitis C patients. <i>Antiviral Therapy</i> , <b>2013</b> , 18, 599-606	1.6	9

109	A forgotten population with chronic hepatitis C infection: subjects coinfecting with hepatitis B virus. <i>Hepatology</i> , <b>2004</b> , 40, 266; author reply 267-8	11.2	9
108	Elimination of Hepatitis B in Highly Endemic Settings: Lessons Learned in Taiwan and Challenges Ahead. <i>Viruses</i> , <b>2020</b> , 12,	6.2	9
107	Progressive accumulation of mutations in the hepatitis B virus genome and its impact on time to diagnosis of hepatocellular carcinoma. <i>Hepatology</i> , <b>2016</b> , 64, 720-31	11.2	9
106	Profile and value of FIB-4 in patients with dual chronic hepatitis C and B. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2019</b> , 34, 410-417	4	9
105	Lack of Interferon Sensitivity-Determining Region in the Genome of Hepatitis B Virus Genotype Ba. <i>Antiviral Therapy</i> , <b>2004</b> , 9, 895-903	1.6	9
104	Acoustic Radiation Force Impulse US Imaging: Liver Stiffness in Patients with Chronic Hepatitis B with and without Antiviral Therapy. <i>Radiology</i> , <b>2018</b> , 288, 293-299	20.5	8
103	Clinical presentations of patients from different age cohorts with biliary tract stone diseases. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2014</b> , 29, 1614-9	4	8
102	Viral Factors Affecting the Clinical Outcomes of Chronic Hepatitis B. <i>Journal of Infectious Diseases</i> , <b>2017</b> , 216, S757-S764	7	8
101	Identification of a liver cirrhosis signature in plasma for predicting hepatocellular carcinoma risk in a population-based cohort of hepatitis B carriers. <i>Molecular Carcinogenesis</i> , <b>2014</b> , 53, 58-66	5	8
100	Patterns of managing chronic hepatitis B treatment-related drug resistance: a survey of physicians in Mainland China, South Korea, Taiwan, and Thailand. <i>Hepatology International</i> , <b>2009</b> , 3, 453-60	8.8	8
99	Kinetics of hepatitis B virus reactivation after chemotherapy: more questions than answers. <i>Gastroenterology</i> , <b>2006</b> , 131, 1656; author reply 1656-7	13.3	8
98	Molecular cloning and expression of woodchuck granulocyte-macrophage colony stimulating factor*. <i>Journal of Medical Virology</i> , <b>2001</b> , 65, 567-575	19.7	8
97	Extrahepatic Malignancy Among Patients With Chronic Hepatitis C After Antiviral Therapy: A Real-World Nationwide Study on Taiwanese Chronic Hepatitis C Cohort (T-COACH). <i>American Journal of Gastroenterology</i> , <b>2020</b> , 115, 1226-1235	0.7	8
96	Efficacy and safety of 12 weeks of daclatasvir, asunaprevir plus ribavirin for HCV genotype-1b infection without NS5A resistance-associated substitutions. <i>Journal of the Formosan Medical Association</i> , <b>2019</b> , 118, 556-564	3.2	8
95	Early antiviral therapy reduces the risk of lymphoma in patients with chronic hepatitis C infection. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2019</b> , 49, 331-339	6.1	8
94	Serum Mac-2-Binding Protein Glycosylation Isomer at Virological Remission Predicts Hepatocellular Carcinoma and Death in Chronic Hepatitis B-Related Cirrhosis. <i>Journal of Infectious Diseases</i> , <b>2020</b> , 221, 589-597	7	7
93	Advanced hepatic fibrosis and steatosis are associated with persistent alanine aminotransferase elevation in chronic hepatitis C patients negative for hepatitis C virus RNA during pegylated interferon plus ribavirin therapy. <i>Journal of Infectious Diseases</i> , <b>2015</b> , 211, 1429-36	7	7
92	Baseline Mac-2 Binding Protein Glycosylation Isomer Level Stratifies Risks of Hepatocellular Carcinoma in Chronic Hepatitis B Patients with Oral Antiviral Therapy. <i>Liver Cancer</i> , <b>2020</b> , 9, 207-220	9.1	7

91	Antiviral Therapy in Patients With Chronic Hepatitis C Is Associated With a Reduced Risk of Parkinsonism. <i>Movement Disorders</i> , <b>2019</b> , 34, 1882-1890	7	7
90	Peginterferon plus weight-based ribavirin for treatment-naïve hepatitis C virus genotype 2 patients not achieving rapid virologic response: a randomized trial. <i>Scientific Reports</i> , <b>2015</b> , 5, 11710	4.9	7
89	Peginterferon alfa-2a plus Weight-Based or Flat-Dose Ribavirin for Treatment-Naïve Hepatitis C Virus Genotype 2 Rapid Responders: A Randomized Trial. <i>Scientific Reports</i> , <b>2015</b> , 5, 15255	4.9	7
88	Mixed hepatitis B virus genotype infections: the more, the worse?. <i>Hepatology</i> , <b>2006</b> , 44, 770	11.2	7
87	Sofosbuvir/velpatasvir for patients with chronic hepatitis C virus infection and compensated liver disease: real-world data in Taiwan. <i>Hepatology International</i> , <b>2021</b> , 15, 338-349	8.8	7
86	Factors associated with treatment failure of direct-acting antivirals for chronic hepatitis C: A real-world nationwide hepatitis C virus registry programme in Taiwan. <i>Liver International</i> , <b>2021</b> , 41, 1265-1277	7.9	7
85	Real-world effectiveness and safety of sofosbuvir and ledipasvir with or without ribavirin for patients with hepatitis C virus genotype 1 infection in Taiwan. <i>PLoS ONE</i> , <b>2018</b> , 13, e0209299	3.7	7
84	Src-homology protein tyrosine phosphatase-1 agonist, SC-43, reduces liver fibrosis. <i>Scientific Reports</i> , <b>2017</b> , 7, 1728	4.9	6
83	Value of interleukin-28B genetic polymorphism on retreatment outcomes of chronic hepatitis C genotype 1 relapsers by peginterferon alfa plus ribavirin. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2014</b> , 29, 102-9	4	6
82	Human leukocyte antigen-DRB1*1101 correlates with less severe hepatitis in Taiwanese male carriers of hepatitis B virus. <i>Journal of Medical Virology</i> , <b>2009</b> , 81, 588-93	19.7	6
81	Disease progression in a patient with nonalcoholic steatohepatitis. <i>Journal of the Formosan Medical Association</i> , <b>2008</b> , 107, 816-21	3.2	6
80	Discontinuation of lamivudine treatment for hepatitis flare after kidney or heart transplantation in hepatitis B surface antigen-positive patients: A retrospective case series. <i>Clinical Therapeutics</i> , <b>2006</b> , 28, 1327-34	3.5	6
79	Molecular assays for hepatitis B virus infection. <i>Hepatology</i> , <b>2003</b> , 38, 1311	11.2	6
78	Subgenotypes of hepatitis B virus genotype C in Taiwan. <i>Journal of Infectious Diseases</i> , <b>2005</b> , 192, 1308-9; author reply 1309	7	6
77	Influence of metabolic syndrome, viral genotype and antiviral therapy on superimposed fatty liver disease in chronic hepatitis C. <i>Antiviral Therapy</i> , <b>2005</b> , 10, 405-15	1.6	6
76	Hepatitis B virus Quantification and Detection of YMDD Mutants in a Single Reaction by Real-Time PCR and Annealing Curve Analysis. <i>Antiviral Therapy</i> , <b>2008</b> , 13, 469-480	1.6	6
75	Prevalence and clinical implications of IL28B genotypes in Taiwanese patients with chronic hepatitis C. <i>Journal of the Formosan Medical Association</i> , <b>2016</b> , 115, 953-960	3.2	5
74	Association of IL28B genotypes with metabolic profiles and viral clearance rate in chronic hepatitis C patients. <i>Hepatology International</i> , <b>2013</b> , 7, 171-9	8.8	5

73	HCV core gene polymorphisms correlate with liver fibrosis but not sustained virological response in patients with genotype 1 infection. <i>Antiviral Therapy</i> , <b>2011</b> , 16, 227-35	1.6	5
72	Interferon-based therapy for dialysis patients with chronic hepatitis C: progress and challenges. <i>Nephrology</i> , <b>2007</b> , 12, 8-10	2.2	5
71	Dynamics of hepatitis B e antigen index ratio correlate with treatment response in chronic hepatitis B patients. <i>Liver International</i> , <b>2007</b> , 27, 235-9	7.9	5
70	Hepatitis B virus genotype: What should the clinician know?. <i>Current Hepatitis Reports</i> , <b>2007</b> , 6, 17-23		5
69	Serum hepatitis B core-related antigen level stratifies risk of disease progression in chronic hepatitis B patients with intermediate viral load. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2021</b> , 53, 908-918	6.1	5
68	Rapid Prediction of Treatment Futility of Boceprevir with Peginterferon-Ribavirin for Taiwanese Treatment Experienced Hepatitis C Virus Genotype 1-Infected Patients. <i>PLoS ONE</i> , <b>2015</b> , 10, e0137852	3.7	5
67	Helicobacter pylori infection combined with non-alcoholic fatty liver disease increase the risk of atherosclerosis: Focus in carotid artery plaque. <i>Medicine (United States)</i> , <b>2019</b> , 98, e14672	1.8	5
66	Pathologic findings of patients with nonalcoholic fatty liver disease and the impact of concurrent hepatitis B virus infection in Taiwan. <i>Journal of the Formosan Medical Association</i> , <b>2020</b> , 119, 1476-1482	3.2	4
65	Implications of Hepatitis B Virus Genomic Variations on Treatment Outcomes. <i>Current Pharmacogenomics and Personalized Medicine</i> , <b>2010</b> , 8, 280-288	0.4	4
64	Core promoter mutations of hepatitis B virus and hepatocellular carcinoma: story beyond A1762T/G1764A mutations. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2008</b> , 23, 347-50	4	4
63	Pegylated interferons for the treatment of chronic hepatitis B. <i>Recent Patents on Anti-infective Drug Discovery</i> , <b>2006</b> , 1, 85-94	1.6	4
62	Antiviral therapy against chronic hepatitis C is associated with a reduced risk of oral cancer. <i>International Journal of Cancer</i> , <b>2020</b> , 147, 901-908	7.5	4
61	Whole genome deep sequencing analysis of viral quasispecies diversity and evolution in HBeAg seroconverters. <i>JHEP Reports</i> , <b>2021</b> , 3, 100254	10.3	4
60	Sofosbuvir/velpatasvir with or without low-dose ribavirin for patients with chronic hepatitis C virus infection and severe renal impairment. <i>Gut</i> , <b>2022</b> , 71, 176-184	19.2	4
59	Associated factors and clinical implications of serum aminotransferase elevation in scrub typhus. <i>Journal of Microbiology, Immunology and Infection</i> , <b>2016</b> , 49, 941-946	8.5	3
58	Addition of ribavirin to daclatasvir plus asunaprevir for chronic hepatitis C 1b patients with baseline NS5A resistance-associated variants improved response. <i>Journal of the Formosan Medical Association</i> , <b>2017</b> , 116, 295-299	3.2	3
57	Paritaprevir/ritonavir, ombitasvir plus dasabuvir for East Asian non-cirrhotic hepatitis C virus genotype 1b patients receiving hemodialysis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2019</b> , 34, 1977-1983	4	3
56	NOhep: Toward Global Control of Hepatitis B Virus Infection-An Introduction. <i>Journal of Infectious Diseases</i> , <b>2017</b> , 216, S749	7	3



55	Boceprevir-based triple therapy to rescue HCV genotype 1/HBV dually infected patients refractory to peginterferon plus ribavirin combination therapy in Taiwan. <i>Journal of the Formosan Medical Association</i> , <b>2018</b> , 117, 497-504	3.2	3
54	Increased cancer risk in patients with haemophilia A: a nationwide population-based 14-year study in Taiwan. <i>Haemophilia</i> , <b>2014</b> , 20, 741-6	3.3	3
53	758 ENTECAVIR PLUS PEGINTERFERON alfa-2a vs. ENTECAVIR ALONE IN THE TREATMENT OF HEPATITIS B e ANTIGEN-POSITIVE CHRONIC HEPATITIS B: AN INTERIM REPORT. <i>Journal of Hepatology</i> , <b>2013</b> , 58, S308	13.4	3
52	Reply.. <i>Hepatology</i> , <b>2007</b> , 46, 947-949	11.2	3
51	Characterization of metastatic tumor antigen 1 and its interaction with hepatitis B virus X protein in NF- $\kappa$ B signaling and tumor progression in a woodchuck hepatocellular carcinoma model. <i>Oncotarget</i> , <b>2016</b> , 7, 47173-47185	3.3	3
50	Association of Lipid Profiles With Hepatitis C Viral Load in Chronic Hepatitis C Patients With Genotype 1 or 2 Infection. <i>American Journal of Gastroenterology</i> , <b>2009</b> , 104, 598-604	0.7	3
49	Lack of interferon sensitivity-determining region in the genome of hepatitis B virus genotype Ba. <i>Antiviral Therapy</i> , <b>2004</b> , 9, 895-903	1.6	3
48	Hepatitis B virus quantification and detection of YMDD mutants in a single reaction by real-time PCR and annealing curve analysis. <i>Antiviral Therapy</i> , <b>2008</b> , 13, 469-80	1.6	3
47	Tu1502 [Ledipasvir/Sofosbuvir is Highly Effective and Safe in Patients with Chronic Hepatitis B Virus and Hepatitis C Virus Coinfection: Final Study Results. <i>Gastroenterology</i> , <b>2019</b> , 156, S-1345	13.3	2
46	Expression of Metastatic Tumor Antigen 1 Splice Variant Correlates With Early Recurrence and Aggressive Features of Hepatitis B Virus-Associated Hepatocellular Carcinoma. <i>Hepatology</i> , <b>2019</b> , 70, 184-197	11.2	2
45	High Risk of Clinical Relapse in Patients With Chronic Hepatitis B Virus Infection After Cessation of Prophylactic Antiviral Therapy for Rituximab-Containing Chemotherapy. <i>Journal of Infectious Diseases</i> , <b>2020</b> , 222, 1345-1352	7	2
44	Sofosbuvir/velpatasvir/voxilaprevir plus ribavirin for chronic hepatitis C patients with direct acting antiviral failures: Implications for viral elimination in Taiwan. <i>Journal of the Formosan Medical Association</i> , <b>2020</b> , 119, 1871-1875	3.2	2
43	Elbasvir/grazoprevir is effective and tolerable for the treatment of HCV GT1-infected patients: A real world multicenter observatory study in Taiwan. <i>Journal of Microbiology, Immunology and Infection</i> , <b>2021</b> , 54, 588-595	8.5	2
42	Twelve weeks of ledipasvir/sofosbuvir all-oral regimen for patients with chronic hepatitis C genotype 2 infection: Integrated analysis of three clinical trials. <i>Hepatology Research</i> , <b>2020</b> , 50, 1109-1117 <sup>51</sup>	5.1	2
41	Elbasvir/grazoprevir for hepatitis C virus genotype 1b East-Asian patients receiving hemodialysis. <i>Scientific Reports</i> , <b>2020</b> , 10, 9180	4.9	2
40	Sustained virological response to hepatitis C therapy does not decrease the incidence of systemic lupus erythematosus or rheumatoid arthritis. <i>Scientific Reports</i> , <b>2020</b> , 10, 5372	4.9	2
39	Increased risk of pulmonary tuberculosis in patients with gastroesophageal reflux disease. <i>International Journal of Tuberculosis and Lung Disease</i> , <b>2016</b> , 20, 265-70	2.1	2
38	Clinical significance of occult hepatitis B virus infection cannot be overlooked. <i>Clinical Infectious Diseases</i> , <b>2006</b> , 42, 583-4	11.6	2

37	Long-term evolution of estimated glomerular filtration rate in patients with antiviral treatment for hepatitis C virus infection.. <i>Clinical Gastroenterology and Hepatology</i> , <b>2022</b> ,	6.9	2
36	Longitudinal change of metabolite profile and its relation to multiple risk factors for the risk of developing hepatitis B-related hepatocellular carcinoma. <i>Molecular Carcinogenesis</i> , <b>2020</b> , 59, 1269-1279 <sup>5</sup>		2
35	Evolution of estimated glomerular filtration rate in human immunodeficiency virus and hepatitis C virus-coinfected patients receiving sofosbuvir-based direct-acting antivirals and antiretroviral therapy. <i>Journal of Viral Hepatitis</i> , <b>2021</b> , 28, 887-896	3.4	2
34	Limited drug-drug interaction of elbasvir/grazoprevir for chronic hepatitis C. <i>Journal of the Formosan Medical Association</i> , <b>2020</b> , 119, 933-940	3.2	2
33	Immortal time bias in retrospective analysis: comment on efficacy and safety of long-term treatment with lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma. <i>Blood Cancer Journal</i> , <b>2015</b> , 5, e283	7	1
32	Effects and safety of body positioning on back pain after transcatheter arterial chemoembolization in people with hepatocellular carcinoma: A randomized controlled study. <i>International Journal of Nursing Studies</i> , <b>2020</b> , 109, 103641	5.8	1
31	Micro-evolution of the hepatitis B virus genome in hepatitis B e-antigen-positive carriers: comparison of genotypes B and C at various immune stages. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2015</b> , 30, 172-7	4	1
30	Commentary: treatment of hepatitis C-related cirrhosis in the era of direct-acting anti-virals. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2014</b> , 39, 1427-8	6.1	1
29	Host genetic variants and hepatitis B virologic features in HBeAg-negative hepatitis B carriers with long-term biochemical remission. <i>Hepatology International</i> , <b>2012</b> , 6, 598-605	8.8	1
28	Transabdominal ultrasound finding and acute hepatocellular injury in different cohorts of elderly adults with and without common bile duct stones. <i>Journal of the American Geriatrics Society</i> , <b>2013</b> , 61, 1221-4	5.6	1
27	Metabolic syndrome on top of chronic hepatitis B: the more, the worse?. <i>Gut</i> , <b>2010</b> , 59, 276-7; author reply 277	19.2	1
26	Reactivation of hepatitis B virus in an inactive hepatitis B carrier with glucocorticoid pulse therapy. <i>Digestive and Liver Disease</i> , <b>2009</b> , 41, 322-3	3.3	1
25	Ledipasvir/Sofosbuvir for Patients Coinfected With Chronic Hepatitis C and Hepatitis B in Taiwan: Follow-up 108 Weeks Posttreatment. <i>Clinical Infectious Diseases</i> , <b>2021</b> ,	11.6	1
24	Hepatitis C and hepatitis B coinfection <b>2020</b> , 182-188		1
23	Hepatitis C virus reinfection in patients on haemodialysis after achieving sustained virologic response with antiviral treatment. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2021</b> ,	6.1	1
22	Long-term risk of end-stage renal diseases with maintenance dialysis among chronic hepatitis C patients after antiviral therapy in Taiwan. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2021</b> , 36, 2247-2254	4	1
21	Changing epidemiology of liver disease in Asia: Dual infection of HBV and HCV. <i>Liver International</i> , <b>2021</b> ,	7.9	1
20	Impact of PNPLA3 p.I148M and Hepatic Steatosis on Long-Term Outcomes for Hepatocellular Carcinoma and HBsAg Seroclearance in Chronic Hepatitis B.. <i>Journal of Hepatocellular Carcinoma</i> , <b>2022</b> , 9, 301-313	5.3	1

19	Age and gender may be the key points in hyperglycemic patients with Helicobacter pylori infection combined colorectal adenoma. <i>Helicobacter</i> , <b>2018</b> , 23, e12473	4.9	o
18	Relationship between serum gamma-glutamyl transferase level and colorectal adenoma. <i>PLoS ONE</i> , <b>2020</b> , 15, e0240445	3.7	o
17	Combined viral quasispecies diversity and hepatitis B core-related antigen predict off-nucleos(t)ide analog durability in HBeAg-negative patients. <i>Hepatology International</i> , <b>2021</b> , 15, 582-592	8.8	o
16	Hepatitis C virus eradication decreases the risks of liver cirrhosis and cirrhosis-related complications (Taiwanese chronic hepatitis C cohort). <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2021</b> , 36, 2884-2892	4	o
15	Investigating the prevalence and clinical effects of hepatitis delta viral infection in Taiwan. <i>Journal of Microbiology, Immunology and Infection</i> , <b>2021</b> , 54, 901-908	8.5	o
14	Sofosbuvir/velpatasvir plus ribavirin for Child-Pugh B and Child-Pugh C hepatitis C virus-related cirrhosis. <i>Clinical and Molecular Hepatology</i> , <b>2021</b> , 27, 575-588	6.9	o
13	Occult Hepatitis B Infection <b>2021</b> , 411-425		o
12	Gut-flora metabolites is not associated with synchronous carotid artery plaque and non-alcoholic fatty liver disease in asymptomatic adults: A STROBE-compliant article. <i>Medicine (United States)</i> , <b>2021</b> , 100, e27048	1.8	o
11	Long-term outcome of liver complications in patients with chronic HBV/HCV co-infection after antiviral therapy: a real-world nationwide study on Taiwanese Chronic Hepatitis C Cohort (T-COACH). <i>Hepatology International</i> , <b>2021</b> , 15, 1109-1121	8.8	o
10	ssHepatocellular carcinoma after treatment cessation in non-cirrhotic HBeAg-negative chronic hepatitis B: A multicenter cohort study. <i>Liver International</i> , <b>2021</b> ,	7.9	o
9	Sofosbuvir/Velpatasvir for Hepatitis C Virus Infection: Real-World Effectiveness and Safety from a Nationwide Registry in Taiwan.. <i>Infectious Diseases and Therapy</i> , <b>2021</b> , 11, 485	6.2	o
8	Helicobacter pylori infection and increased diabetes prevalence were the risks of colorectal adenoma for adults: A systematic review and meta-analysis (PRISMA-compliant article).. <i>Medicine (United States)</i> , <b>2021</b> , 100, e28156	1.8	o
7	A simple non-invasive test for ruling out cirrhosis in chronic hepatitis B. <i>The Lancet Gastroenterology and Hepatology</i> , <b>2019</b> , 4, 495-496	18.8	
6	Research Highlights: Pharmacogenomics of chronic hepatitis C. <i>Pharmacogenomics</i> , <b>2009</b> , 10, 1039-1042	2.6	
5	Acute fatty liver of pregnancy with concurrent acute hepatitis B virus infection. <i>American Journal of Gastroenterology</i> , <b>2008</b> , 103, 2663-5	0.7	
4	Sequential combination therapy for chronic hepatitis B: more challenges to be tackled. <i>American Journal of Gastroenterology</i> , <b>2007</b> , 102, 1544; author reply 1545	0.7	
3	Effects of infection in gastrointestinal tract malignant diseases: From the oral cavity to rectum.. <i>World Journal of Gastrointestinal Oncology</i> , <b>2022</b> , 14, 55-74	3-4	
2	Interspousal transmission of TT virus: Low efficiency and lack of apparent risk factors. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2000</b> , 15, 1287-1291	4	

1 Treatment options for dual HCV/HBV coinfection **2013**, 72-84